Loading clinical trials...
Loading clinical trials...
Benralizumab is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β2-ago...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
AstraZeneca
NCT05691218 · Moderate Asthma Exacerbation, Severe Asthma Exacerbation
NCT03984253 · Severe Asthma
NCT06681545 · Asthma, Severe Asthma, and more
NCT06385236 · Moderate to Severe Asthma
NCT07343661 · EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma, and more
Hospital Prof. Dr. Fernando Fonseca
Amadora
HSMM
Barcelos
CHUC - Imunoalergologia
Coimbra
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions